Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Pulmonary hypertension (PH) has emerged as a critical cause of death in systemic sclerosis (SSc). Recent data have highlighted the poorer outcomes of SSc associated PAH as compared to the idiopathic forms. Therefore, the management of SSc patients at risk of PAH risk must be improved to allow early diagnosis. However, there is presently no guideline regarding the parameters that should lead the physician to perform right heart catheterization, the only tool unequivocally establishing the correct diagnosis. Our aim was, by consensus, to identify the most appropriate indications for RHC in patients with SSc.
Methods: A three-stage Delphi exercise involving worldwide PH experts was designed to answer the following question: “based on which parameters, performed on the basis of an annual screening of SSc patients in clinical practice, do you decide to refer patients for RHC?”. The Delphi exercise was performed between March 2011 and December 2011.
The aim of the first stage was to obtain a comprehensive list of domains and tools to be considered before referring a SSc patient for RHC. This list combined evidence-based indications extracted from published reports on SSc-PH and expert opinions. For the second stage, experts were asked to rate each item proposed in the list, using a 5-point scale (1 indicates “not important/appropriate at all” and 5 indicates “very important/appropriate”). For the third stage, experts were asked to rate the items accepted after the second round, using the same 5-point scale. After each of stages 2 and 3, the number of domains and tools was reduced according to a cluster analysis. The number of clusters was generated by an automatic cluster algorithm using Bayes information criterion.
Results: 77 experts were contacted by e-mail to participate in this Delphi procedure. 47 (61%) participated in stage 1, 50 (65% of the 77) in stage 2, and 48 (62% of the 77) in stage 3. The list obtained after the first stage consisted on 7 domains (clinical, biomarkers, pulmonary function tests, echocardiography, cardiopulmonary exercise, imaging and EKG) containing a total of 142 tools. Cluster analysis performed after the second stage allowed discarding of 63 of the 142 initial tools. Cluster analysis performed after stage 3 reduced the EPOSS instrument to 3 domains containing 8 items (see table).
Domains
|
Tools
|
Mean ratings (5-point scale)
|
Clinical tools
|
*Progressive dyspnea over the last 3 months *Unexplained dyspnea *Worsening in WHO dyspnea functional class *Any finding on physical examination suggestive of elevated right heart pressures (Jugular venous distension, accentuated S2, TR murmur, etc) *Any sign of right heart failure |
4.4 4.3 4.4 4.4 4.8 |
Echocardiography
|
* sPAP>45 mmHg * Dilation of right ventricle |
4.3 4.3 |
Pulmonary function tests
|
* DLCO<50% without pulmonary fibrosis |
4.4 |
Conclusion: Among experts in PH-SSc, a core set of indications for clinical practice has been defined to refer SSc patients to RHC in case of PH suspicion. This EPOSS instrument is the first expert guidelines for PH detection that is based on validated consensus methods. Although these indications are recommended by this expert group, it is an interim tool. It will be necessary to formally validate and extend the EPOSS instrument in further studies, both for clinical practice and in terms of additional research.
Disclosure:
J. Avouac,
Actelion Pharmaceuticals US,
2,
Pfizer Inc,
2;
D. Huscher,
None;
D. Furst,
Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,
2,
Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,
5,
Abbott, Actelion, UCB ,
8;
O. Distler,
Actelion, Bayer. Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science and Active Biotec ,
2,
Actelion, Bayer. Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science and Active Biotec ,
5,
Actelion, Pfizer and Ergonex,
8;
Y. Allanore,
Actelion Pharmaceuticals US,
2,
Pfizer Inc,
2.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/expert-consensus-for-performing-right-heart-catheterization-in-suspicion-of-pulmonary-arterial-hypertension-associated-with-systemic-sclerosis-a-delphi-consensus-study-with-cluster-analysis-from-the/